Merck KGaA (OTCMKTS:MKKGY - Get Free Report) is expected to announce its earnings results before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of $0.47 per share and revenue of $5.40 billion for the quarter.
Merck KGaA Price Performance
MKKGY traded up $0.26 during trading on Friday, reaching $28.21. 93,666 shares of the company traded hands, compared to its average volume of 137,527. The company has a market cap of $18.23 billion, a P/E ratio of 17.41, a PEG ratio of 2.05 and a beta of 0.95. Merck KGaA has a 12-month low of $27.68 and a 12-month high of $39.17. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.91 and a current ratio of 1.33. The firm has a fifty day simple moving average of $29.18 and a 200 day simple moving average of $32.20.
About Merck KGaA
(
Get Free Report)
Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector.
Read More
Before you consider Merck KGaA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck KGaA wasn't on the list.
While Merck KGaA currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
